Medication info
Trip Em Duo Tablet 2.5/850 mg (Linagliptin, Metformin)

Trip Em Duo Tablet 2.5/850 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Orange, biconvex, oval, film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401056 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is co-administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is co-administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they have no other condition that may increase the risk of lactic acidosis, and the following dose adjustments are made. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Contraindications).

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is used to assist in the blood sugar control of patients with type 2 diabetes by using Linagliptin and Metformin together. It helps manage blood sugar levels effectively while following a dietary regimen and exercise. This contributes to the prevention of complications related to diabetes and maintaining a healthy life. Therefore, this drug is used to improve blood sugar control in conjunction with dietary and exercise therapy.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is co-administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is co-administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they have no other condition that may increase the risk of lactic acidosis, and the following dose adjustments are made. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Contraindications).

Precautions

This drug is used for the treatment of diabetes. However, it should not be administered to patients with poor kidney function or severe liver dysfunction. Rare but serious side effects such as lactic acidosis may occur, so kidney and liver function should be checked periodically. Also, patients with unstable heart function or cardiovascular diseases such as acute myocardial infarction should avoid using this drug. Pregnant or breastfeeding women should not take this drug. This drug has a risk of hypoglycemia, so when used in conjunction with insulin or sulfonylurea class medications, blood sugar conditions should be carefully monitored. If symptoms such as abdominal pain, severe muscle pain, difficulty breathing, or weakness occur during use, consult a doctor immediately. Rare side effects such as acute pancreatitis or bullous pemphigoid with skin blisters may occur, so if such symptoms arise, discontinue the medication and consult a specialist. This drug may lower vitamin B12 levels, so regular testing of vitamin B12 levels is necessary during long-term use. Furthermore, caution should be taken when taken with other medications that can affect kidney function, and dosage adjustment may be required as needed. In special situations such as surgery or radiation examinations, the use of this drug should be temporarily suspended, and resumption should occur only after kidney function stabilizes. Elderly patients are at higher risk of reduced kidney function, so kidney function should be monitored frequently, and appropriate dosage adjustments should be made when using this drug. The safety and efficacy of this drug in children have not been fully established, thus it is not recommended for children under 10 years old. Lastly, this drug should be stored out of reach of children and kept away from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 123 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • jejunoileitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypercholesterolemia
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anxiety
  • affective disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • benign prostatic hyperplasia
  • itching
  • disorientation
  • nocturia
  • dermatitis
  • hypertension
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased serum creatinine
  • facial swelling
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • subdural effusion
  • palpitations

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius (room temperature). This will help maintain the effectiveness and safety of the drug for an extended period.

Appearance and packaging

Appearance

Orange, biconvex, oval, film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.